Aries Science & Technology and Enveric Biosciences Announce Issuance Of Key U.S. Patent No. 12,059,393 Under Aries' License For Treatment Of Radiation Dermatitis And Other Conditions
Portfolio Pulse from Benzinga Newsdesk
Enveric Biosciences and Aries Science & Technology have announced the issuance of a key U.S. patent for a topical product aimed at treating radiation dermatitis. The patent strengthens Enveric's portfolio and is part of a Licensing Agreement between Enveric's subsidiary Akos Biosciences and Aries. The market opportunity for this treatment is estimated at $400 million annually.
August 13, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Enveric Biosciences has announced the issuance of a key U.S. patent for a topical product aimed at treating radiation dermatitis, which strengthens its patent portfolio and has a significant market opportunity.
The issuance of a key patent and the significant market opportunity for the new product are likely to positively impact Enveric's stock price in the short term. The patent strengthens Enveric's intellectual property portfolio, which is crucial for biotech companies.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100